Last checked at 
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.
----------
AIM - WINNERS
----------
Velocity Composites PLC, up 22% at 24.4 pence, 12-month range 12.05p-25.9p. Hits this 12-month high earlier on Friday. The supplier of advanced composite material kits signs three-year contract with a "major Tier 1 aerostructures manufacturer" based in Hampshire. The contract includes both an extension in the term of an existing five-year agreement entered in August 2016 and the award of new business covering the remaining additional programmes in production at the customer site, starting immediately. Contract has expected annual value of GBP4.1 million.
----------
Rockhopper Exploration PLC, up 14% at 9.7p, 12-month range 4.77p-12.28p. Notes that tribunal in international arbitration against Italy in relation to the Ombrina Mare field anticipates being in position to render its award in July. "Rockhopper continues to believe it has strong prospects of recovering very significant monetary damages - on the basis of lost profits - as a result of the Republic of Italy's breaches of the Energy Charter Treaty. All costs associated with the arbitration are funded on a non-recourse basis from a specialist arbitration funder," company says.
----------
Physiomics PLC, up 8.4% at 6.50p, 12-month range 3.55p-17.25p. Awarded further contract by existing client Merck KGaA that should be completed over next two to three months. This contract follows on from and is additional to the initial tranche of projects with Merck announced in December, with a value of GBP270,000, intended to be completed in the first six to eight months of calendar year 2021.
----------
AIM - LOSERS
----------
e-Therapeutics PLC, down 7.0% at 25.40p, 12-month range 1.01p-33p. Raises GBP22.5 million via placing, subscription and retail offer. Placing comprised 81.2 million shares at 24p each to raise GBP19.5 million, while it will issue 8.7 million shares under the subscription, raising GBP2.1 million. Says 3.8 million shares to be issued until retail offer, raising GBP920,000. The proceeds of the fundraising will go towards several initiatives, including expanding the company's proprietary, disease-agnostic, drug discovery and development platform capabilities and asset pipeline.
----------
By Lucy Heming;Â lucyheming@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.